Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments - Research and Markets

Research and Markets
Posted on: 02 Aug 17

The "Global Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments" report has been added to Research and Markets' offering.

Pipeline Overview

Idiopathic pulmonary fibrosis (IPF) is referred to as progressive and chronic interstitial pneumonia without known cause. Pulmonary fibrosis is a disease in which tissue profound in lungs becomes stiff and dense over time.

The scar tissue formation is known as fibrosis. As the fibrosis progresses and tissue become darker, lungs can't properly move oxygen into the bloodstream, which result in oxygen deficiency in brain and other organs.

IPF usually affects older adults and middle-aged people and it has no cure till now. The major cause of death in IPF's patients is respiratory failure. Pulmonary hypertension, heart failure, pulmonary embolism, pneumonia and lung cancer are the other causes of the death for IPF patient.

With the progress in research for IPF, it is now more quickly diagnosed and many drugs are also being discovered for its treatment. This will improve the quality of life of patients and will also increase their lifespan.

Bronchoscopy and surgical lung biopsy are used as testing procedures. In Bronchoscopy, lymphocytosis in bronchoalveolar lavage fluid is absent which is observed for the diagnosis. The best sample for characteristic usual interstitial pneumonia from other idiopathic interstitial pneumonias is surgical lung biopsy.

The treatment for IPF as optimal medical cure has yet to be identified. This creates ample growth opportunities for pharmaceutical companies, as there is very low competition due to lack of approved drugs.

Current treatment approaches for IPF include the management and assessment of comorbid conditions per present practice guidelines, including obstructive sleep apnea, chronic obstructive pulmonary disease, coronary artery disease and gastroesophageal reflux disease.

Key Topics Covered:

1. Research Scope And Methodology

2. Executive Summary

3. Pipeline Outlook

4. Global Idiopathic Pulmonary Fibrosis (Ipf) Pipeline Analysis By Phase (2016)

5 Competitive Landscape

6 Company Profiles

7 Appendix

For more information about this report visit

View source version on

Business Wire

Last updated on: 02/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.